WVE
Wave Life Sciences, Inc.
Set alert
3.59 USD -0.04 -1.10%
3.43 Day range 3.70
3.09 52-week range 21.31
- YTD
- -78.88%
- 1 year
- -56.75%
- Open
- 3.62
- Prev close
- 3.63
- Mkt cap
- 708.05M
- Vol
- 3.33M
- Avg vol
- 3.30M
- EPS
- -1.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.43
- High
- 3.70
- Forward P/E
- -4.33
- Beta
- -1.29
- Short ratio
- 5.75
- Inst. own
- 85.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 5.77
- 200-d avg
- 9.39
- 1y target
- 19.06
Key statistics
- Market cap
- 1.02B
- Enterprise value
- 583.55M
- Trailing P/E
- 0.00
- Forward P/E
- -4.33
- PEG ratio
- 0.00
- Price / sales
- 15.55
- Price / book
- 1.87
- EPS (TTM)
- -1.08
- Beta
- -1.29
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 65.37M
- Revenue growth
- -73.90%
- Free cash flow
- -128.78M
- Total cash
- 490.60M
- Total debt
- 43.59M
- Return on equity
- -67.42%
- Shares outstanding
- 197.05M
- Short % of float
- 10.14%
- 50-day average
- 5.77
- 200-day average
- 9.39
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 19.06 +431.0% upside
Now 3.59
- Target (low)
- 12.00
- Target (mean)
- 19.06
- Target (high)
- 42.00
Ratings (0m) 16 16 buy · 0 hold · 0 sell
- Strong buy2
- Buy14
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.31703.
Financials — quick view
WVE Revenue — quarterly 13.16M
WVE Net income — quarterly -61.91M
WVE EPS — quarterly -0.30
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.33 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.29975 | -0.34 | -0.04 | -13.43% |
| Apr 28, 2026 | Mar 31, 2026 | -0.34 | -0.13 | +0.21 | +61.76% |
| Feb 26, 2026 | Dec 31, 2025 | -0.28 | -0.30 | -0.02 | -7.14% |
| Nov 10, 2025 | Sep 30, 2025 | -0.30 | -0.32 | -0.02 | -6.67% |
| Jul 30, 2025 | Jun 30, 2025 | -0.29 | -0.31 | -0.02 | -6.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | Mizuho | main | Outperform | Outperform |
| Jul 31, 2026 | Citigroup | main | Buy | Buy |
| Jul 31, 2026 | B. Riley Securities | main | Buy | Buy |
| Jul 31, 2026 | Wedbush | main | Outperform | Outperform |
| May 20, 2026 | Wells Fargo | main | Overweight | Overweight |
| May 19, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Wave Life Sciences, Inc.
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- wavelifesciences.com
News
- Canaccord Genuity Maintains Buy on Wave Life Sciences, Raises Price Target to $44
- Oppenheimer Maintains Outperform on Wave Life Sciences, Lowers Price Target to $29
- Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript
- WAVE Life Sciences Q3 Earnings Call Highlights
- Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
- Wave Life Sciences Anticipates $12M Milestone Payment From GSK In Q4
- WAVE Life Sciences Q3 EPS $(0.30) Beats $(0.33) Estimate, Sales $13.158M Beat $4.317M Estimate
- Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
- WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
- Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
Your note
Sign in to keep a note on WVE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOLNO PAUL B. M.D. | Chief Executive Officer | Sale | Feb 8, 2026 | 275,520 |
| CORRIGAN MARK | Director | Sale | Dec 7, 2025 | 28,815 |
| FRANCIS CHRISTOPHER JOHN | Officer | Conversion of Exercise of derivative security | Feb 25, 2026 | 61,867 |
| GSK PLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 10, 2025 | 0 |
| MORAN KYLE | Chief Financial Officer | Sale | Feb 8, 2026 | 134,385 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 29, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kennedy Capital Management, LLC | 0.00% | 429,121 | 2.21M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 2.09% | 4,111,308 | 21.21M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.83% | 3,598,451 | 18.57M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.16% | 2,287,103 | 11.80M | Mar 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1.07% | 2,107,233 | 10.87M | Mar 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.84% | 1,659,857 | 8.56M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.82% | 1,610,961 | 8.31M | Mar 30, 2026 |